|1.||Bitzer, Johannes: 4 articles (10/2013 - 01/2010)|
|2.||Karakurt, Feridun: 3 articles (01/2014 - 04/2008)|
|3.||Rosendaal, Frits R: 3 articles (01/2014 - 01/2013)|
|4.||Rabe, Thomas: 3 articles (07/2013 - 01/2003)|
|5.||Arowojolu, Ayodele O: 3 articles (01/2012 - 01/2009)|
|6.||Lopez, Laureen M: 3 articles (01/2012 - 01/2009)|
|7.||Grimes, David A: 3 articles (01/2012 - 01/2009)|
|8.||Gallo, Maria F: 3 articles (01/2012 - 01/2009)|
|9.||Luque-Ramírez, Manuel: 3 articles (06/2009 - 07/2007)|
|10.||Alvarez-Blasco, Francisco: 3 articles (06/2009 - 07/2007)|
01/01/1990 - "Cyproterone acetate given as a single intramuscular dose of 300 mg monthly for 6 months resulted in significant reduction of hirsutism without appreciable side effects. "
01/01/2003 - "The major outcomes included: subjective improvement in hirsutism, changes in Ferriman Gallwey scores, changes in linear hair growth and hair shaft diameter, alterations in endocrine parameters, side effects to treatment, withdrawals during therapy There were no clinical trials comparing cyproterone acetate alone with placebo. "
11/01/1978 - "The administration of cyproterone acetate can be effective in the treatment of 'idiopathic' hirsutism. "
07/01/1991 - "Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study."
01/01/1987 - "In the present study a parenteral treatment regimen with cyproterone acetate was compared with the high dose peroral administration in patients with severe hirsutism. "
01/01/2006 - "In this study we evaluated the efficacy of cyproterone acetate alcohol lotion (CAAL) in the treatment of the mild to moderate acne vulgaris. "
01/01/2006 - "The efficacy of topical cyproterone acetate alcohol lotion versus placebo in the treatment of the mild to moderate acne vulgaris: a double blind study."
01/01/2006 - "Regarding the results of this study, we suggest the use of cyproterone acetate alcohol lotion as one of the main treatments for mild-moderate acne in female patients and as an adjuvant treatment for moderate to severe acne vulgaris."
01/01/2004 - "A COC with cyproterone acetate might result in better acne outcomes than one with desogrestrel; however, the three studies comparing these COCs produced conflicting results. "
04/01/1998 - "Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial."
|3.||Prostatic Neoplasms (Prostate Cancer)
04/29/2000 - "In advanced prostate cancer, addition of an antiandrogen to AS improved the 5-year survival by about 2% or 3% (depending on whether the analysis includes or excludes the cyproterone acetate trials), but the range of uncertainty as to the true size of this benefit runs from about 0% to about 5%."
07/01/2003 - "[Evaluation of efficacy of cyproterone acetate monotherapy in prostatic cancer]."
10/01/2014 - "To compare intermittent treatment (IT) versus continuous treatment (CT) using cyproterone acetate (CPA) in bone metastatic prostate cancer patients, we conducted an open-label, multicenter randomized trial. "
10/01/2014 - "Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial."
06/01/1980 - "Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial."
01/01/1989 - "The therapeutic results warrant the conclusion that cyproterone acetate seems to be effective in androgenetic alopecia in women."
01/01/1989 - "The effect of cyproterone acetate on hair roots and hair shaft diameter in androgenetic alopecia in females."
12/01/2002 - "We report a 66-year-old lady taking 50 mg/day of cyproterone acetate for biopsy proven androgenetic alopecia, who developed this unusual complication of shortness of breath. "
12/01/2002 - "Shortness of breath: an uncommon side-effect of cyproterone acetate in the treatment of androgenetic alopecia."
06/01/2002 - "Effects of minoxidil 2% vs. cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial."
11/01/2014 - "Cyproterone acetate (CPA), a synthetic hormonal drug, induces rat liver tumors in a sex-specific manner, with five-fold higher doses needed to induce liver tumors in male rats compared to females. "
02/01/2008 - "Cyproterone acetate (CPA), a synthetic progestin is not only a genotoxic agent but also a tumor initiating agent. "
12/01/2005 - "Disappearance of a virilizing adrenal tumor following therapy with cyproterone acetate."
06/04/2004 - "The anti-androgen and progestagen cyproterone acetate (CPA) is known to cause liver tumors in rats. "
05/01/2001 - "In agreement with these considerations the regulatory authorities of the European Union came to the common conclusion that a possible cancer risk associated with the clinical use of cyproterone acetate, if any, appears to be low and the risk-benefit ratios for the currently authorised indications remain favourable."
|2.||Ethinyl Estradiol (Estinyl)
|4.||Gonadotropin-Releasing Hormone (GnRH)
|6.||Chlormadinone Acetate (Chlormadinone)
|7.||Levonorgestrel (Plan B)
|9.||Medroxyprogesterone Acetate (Depo-Provera)
|4.||Drug Therapy (Chemotherapy)
|5.||Contraception (Birth Control)